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ORIGINAL ARTICLE
Tumour-associated and non-tumour-associated
microbiota in colorectal cancer
Burkhardt Flemer,1,2 Denise B Lynch,1,2 Jillian M R Brown,1,2 Ian B Jeffery,1,2
Feargal J Ryan,1,2 Marcus J Claesson,1,2 Micheal O’Riordain,3 Fergus Shanahan,1,4
Paul W O’Toole1,2
ABSTRACT
Objective A signature that uniﬁes the colorectal cancer
(CRC) microbiota across multiple studies has not been
identiﬁed. In addition to methodological variance,
heterogeneity may be caused by both microbial and host
response differences, which was addressed in this study.
Design We prospectively studied the colonic microbiota
and the expression of speciﬁc host response genes using
faecal and mucosal samples (‘ON’ and ‘OFF’ the tumour,
proximal and distal) from 59 patients undergoing surgery
for CRC, 21 individuals with polyps and 56 healthy
controls. Microbiota composition was determined by 16S
rRNA amplicon sequencing; expression of host genes
involved in CRC progression and immune response was
quantiﬁed by real-time quantitative PCR.
Results The microbiota of patients with CRC differed
from that of controls, but alterations were not restricted
to the cancerous tissue. Differences between distal and
proximal cancers were detected and faecal microbiota
only partially reﬂected mucosal microbiota in CRC.
Patients with CRC can be stratiﬁed based on higher level
structures of mucosal-associated bacterial co-abundance
groups (CAGs) that resemble the previously formulated
concept of enterotypes. Of these, Bacteroidetes Cluster 1
and Firmicutes Cluster 1 were in decreased abundance
in CRC mucosa, whereas Bacteroidetes Cluster 2,
Firmicutes Cluster 2, Pathogen Cluster and Prevotella
Cluster showed increased abundance in CRC mucosa.
CRC-associated CAGs were differentially correlated with
the expression of host immunoinﬂammatory response
genes.
Conclusions CRC-associated microbiota proﬁles differ
from those in healthy subjects and are linked with
distinct mucosal gene-expression proﬁles. Compositional
alterations in the microbiota are not restricted to
cancerous tissue and differ between distal and proximal
cancers.
INTRODUCTION
Despite advances on several fronts, colorectal
cancer (CRC) is still a major killer of women and
men. Effective prevention requires identiﬁcation of
biomarkers of risk but currently available strategies
are actually based on markers of established, albeit
early, disease or the identiﬁcation of precursor
lesions such as dysplasia and adenomatous polyps.
Since genetic syndromes account for a minority of
cases of CRC,1 factors that predispose to sporadic
mutations offer the best prospect for early
identiﬁcation of individuals at greatest risk. Most
of the known environmental or lifestyle risk
factors for CRC, such as obesity and diets that are
high in fat or red meat,2 also modify the indigen-
ous microbiota. Thus, the microbiota or its meta-
bolites may be the proximate environmental
modiﬁers of risk for colon cancer. One of the
lessons from the relationship between Helicobacter
pylori and gastric cancer is that interindividual
variation may be due to heterogeneity at the level
of either the microbe or the host response.3 In the
case of CRC, the relationship between the micro-
biota and disease may be even more complex;
combinations or co-abundance groups (CAGs) of
Signiﬁcance of this study
What is already known on this subject?
▸ Environmental factors have a strong effect on
the development of colorectal cancer (CRC).
▸ Certain microorganisms have been shown to be
associated with an increased risk of CRC.
▸ No unifying CRC-associated microbiota
structure has been determined.
What are the new ﬁndings?
▸ Individuals with CRC can be stratiﬁed into four
groups based on the abundance of bacterial
co-occurrence networks, resembling the
previously formulated concept of enterotypes.
▸ The altered microbiota composition in the
mucosa of patients with CRC is not restricted
to cancerous tissue.
▸ Faecal microbiota only partially reﬂects
mucosal microbiota in CRC.
▸ CRC-associated bacterial clusters are
differentially correlated with mucosal
gene-expression proﬁles.
How might it impact on clinical practice in
the foreseeable future?
▸ The heterogeneity of the CRC-associated
microbiota identiﬁed could be exploited as a
screening tool for individuals at greatest risk of
developing CRC.
▸ Modiﬁcation of the microbiota could be
integrated into prevention and treatment
strategies for CRC.
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organisms may be operative, rather than representing a one
organism–one disease model.4
Molecular mechanisms linking speciﬁc microbes with colon
carcinogenesis have been identiﬁed in experimental animal
models.5 6 However, studies in humans have been less clear,
confounded in part by difﬁculty distinguishing organisms which
have a primary inﬂuence from those which are passengers or
secondary to the cancer. Various individual organisms have been
reported in association with human colon cancer tissue, the
most consistent being Fusobacterium species,7 8 but the ﬁndings
have not been uniform in all reports nor conclusive. Some of
the variances may be methodological: sampling differences
(faeces vs mucosal tissue) or due to different stages of disease or
true differences between the right and left colon. Heterogeneity
of cancer-associated microbiota might also reﬂect differences in
the host immunoinﬂammatory response to cancer, which is
known to inﬂuence prognosis.9 Despite such heterogeneity of
CRC-associated microbiota, recent studies have suggested the
feasibility of using a combination of several bacteria (or micro-
biota signature) in the faecal microbiota of individuals with
CRC as a marker for detecting the disease.10–12
To address the confounding variables associated with CRC
microbiota studies, we conducted a prospective study of the
colonic microbiota using paired faecal and mucosal samples
(‘ON’ and ‘OFF’ the tumour, proximal and distal) from patients
undergoing surgery for CRC, and the microbiota composition
was correlated with the expression of speciﬁc host response
genes. The results show that individuals with CRC can be strati-
ﬁed into four different groups based on the abundance of bac-
terial co-occurrence networks, but importantly we have been
able to deﬁne a more complex concept of bacterial abundance
gradients and community scaffolds rather than discrete bacterio-
types. The altered microbiota of these patients is present on the
mucosa throughout the colon and is not restricted to cancerous
tissue. Moreover, we detected microbiota differences between
individuals with distal (including rectal) tumours and proximal
tumours, and speciﬁc microbiota proﬁles were correlated with
the expression of genes known to regulate the host immunoin-
ﬂammatory response.
MATERIALS AND METHODS
Sampling
CRC patients: In total, 70 individuals scheduled for colonic
resection at Mercy University Hospital, Cork, were recruited to
the study. Exclusion criteria were a personal history of CRC,
IBD or IBS (for description of subjects and clinical data, see
online supplementary table S1). Individuals were not treated
with antibiotics in the month prior to surgery but were adminis-
tered antibiotics intravenously within a few hours of the resec-
tion. After surgery, two samples from up to ﬁve different sites
were collected in RNAlater (Qiagen, Hilden, Germany): OFFD
(off-distal; 2–5 cm towards the distal end of the colon), OFFP
(off-proximal; 2–5 cm towards the proximal end of the colon),
UDD (undiseased distal; as far away from the tumour as possible;
distal; usually 10–30 cm) and UDP (undiseased proximal; as far
away from the tumour as possible; proximal; usually 10–30 cm).
Samples were placed in 3 mL RNAlater, stored at 4°C for 12 h
and then stored at −20°C. Faecal samples were self-sampled
prior to the start of the bowel preparation, transported to the
laboratory on ice and frozen at −80°C. In total, mucosal samples
from 59 individuals and 43 stool samples were collected. For 32
patients, both tissue and stool samples were obtained.
Polyps: Biopsy samples from 21 individuals with polyps were
obtained in RNAlater as described above. Mostly, undiseased
tissue was collected from individuals with polyps because the
small polyp sample was reserved for examination by a patholo-
gist. Up to two biopsies were obtained per individual upon
endoscopy, one from undiseased tissue in the descending colon
and one from undiseased tissue in the ascending colon.
Exclusion criteria included IBD and IBS and the use of antibio-
tics 1 month prior to surgery. No stool samples were sampled
from individuals with polyps.
Healthy controls: Biopsy samples from 56 controls were
obtained in RNAlater as described above. Exclusion criteria
included IBD, IBS and CRC. Up to two biopsies were obtained
per individual upon endoscopy, one from the descending colon
and one from the ascending colon. Stool samples were selected
from a previously collected cohort of healthy elderly people.13
In total, samples from 37 healthy, age-matched individuals were
analysed.
The study was approved by the UCC Ethics Committee under
the study number APC033.
DNA/RNA extraction and 16S rRNA amplicon sequencing
Genomic DNA and total RNA were extracted using the AllPrep
DNA/RNA kit from Qiagen. For tissue samples, ∼20 mg of
tissue was placed into bead tubes with 250 mL of 0.1 mm sterile
glass beads and several 3–4 mm sterile glass beads. Next,
600 mL of buffer RLT (Qiagen) containing 1%
β-mercaptoethanol was added and the sample was homogenised
in a MagnaLyzer (Roche, Penzberg, Germany) for two pulses of
15 s each at full speed. In between the homogenisation steps,
the samples were put on ice for 30 s. The rest of the DNA
extraction was carried out according to the AllPrep DNA/RNA
extraction kit (Qiagen).
16S rRNA gene amplicon sequencing was carried out employ-
ing the 16S Metagenomic Sequencing Library Preparation proto-
col developed by Illumina (San Diego, California, USA). Brieﬂy,
200 ng of mucosal DNA (50 ng for faecal samples) was ampliﬁed
employing primers targeting the V3/V4 variable region of the
16S rRNA gene: 16S amplicon PCR forward primer (V3 region):
50 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCT
ACG GGNGGCWGCAG; 16S amplicon PCR reverse primer
(V4 region): 50 GTCTCGTGGGCTCG GAGATGTGTAT
AAGAGACAGGACTACHVGGGTATCTAATCC.14 The products
were puriﬁed and forward and reverse barcodes were attached
(Nextera XT V.2 Index Kit sets A and D, Illumina).
Amplicons were puriﬁed again and quantiﬁed using a
Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies,
Paisley, UK). Equimolar amounts of DNA per amplicon were
then pooled (314 samples) and sequenced at GATC (Konstanz,
Germany) on a MiSeq sequencing instrument (Illumina) using
2×250 bp chemistry.
Analysis of 16S amplicon sequencing data
Paired end sequencing reads were obtained as demultiplexed
libraries per sample. To avail the quality control step implemen-
ted in QIIMEs15 split_libraries_fastq.py script, barcodes were
reattached to each sequence using custom scripts, adaptors were
removed using cutadapt16 and paired-end reads were merged
using FLASH.17 Libraries were then split using QIIME15 with
the split_libraries_fastq.py script. An operational taxonomic unit
(OTU) table was obtained using usearch18 and the following
procedure. First, unique sequences of length 350–500 nt were
ﬁltered (derep_fulllength) and sorted by length (sortbylength).
The remaining sequences were clustered (cluster_otus) and ﬁl-
tered for chimaeras against the ChimeraSlayer reference data-
base.19 Finally, all sequences were mapped against this database
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(usearch_global) and an OTU table was obtained using uc2otu-
tab.py. Classiﬁcation of representative sequences for each OTU
was carried out using mothur20 against the 16S rRNA reference
of RDP, V.14. A similar approach was employed for analysing
16S rRNA sequencing data that we obtained from two previous
studies,11 21 with the exception that quality ﬁltering of the pyro-
sequencing data from Kostic et al was carried out according to
the 454 standard operating procedure in mothur.22 Identical
sequencing depth per sample was ensured by rariﬁcation to
5000 sequences per sample for this cohort; to 10 000 sequences
per sample for data from Zeller et al; and to 2000 sequences
per sample for data from Kostic et al. Samples with less
sequences were not included in the analysis.
Reverse-transcription real-time quantitative PCR
Total RNA was treated with DNase (TURBO DNA-free, Life
Technologies) according to the instructions of the supplier. The
treated RNA was then analysed on a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, California, USA) and only used if the
RNA integrity number was above 7. Reverse transcription was
carried out using 250 ng of RNA, Transcriptor Reverse
Transcriptase, primer ‘random’, PCR nucleotide mix and
Protector RNase inhibitor (all Roche) as per instructions of the
manufacturer. Real-time quantitative PCR (RT-qPCR) was
carried out on a LightCycler 480 (Roche) targeting several
genes published as being putatively involved in inﬂammation
and cancer progression using primers and probes designed with
the Universal ProbeLibrary Assay Design Center (Roche). For
primer sequences, see online supplementary table S2. The
master mix comprised 5 mL SensiMix II Probe No-ROX mix
(BIOLINE, London, UK), 2 mM forward and reverse primer,
2.5 mL DNA and water to 10 mL. The program employed was
95°C for 10 min, 95°C for 10 , 60°C for 45 s, 72°C for 1 s,
with the last three steps repeated 45 times. The relative expres-
sion of each gene was calculated using the 2−ΔΔCt method.23
The expression was normalised to the average expression of all
control individuals. The housekeeping gene used was β-actin.
Statistical analysis
Statistical analysis was carried out in R.24 Paired or non-paired
t test or Wilcoxon tests were employed to analyse differences in
the abundance between two groups, for normally or not nor-
mally distributed data, respectively. To test for differences in the
overall microbiota between sample groups, permutational multi-
variate analysis of variance using distance matrices (pMANOVA)
was employed to assess the signiﬁcance (function ‘adonis’ of the
vegan package in R). This method works analogously to
MANOVA but does not need to make assumptions about the
distribution of the input values.25 Distance matrices were calcu-
lated using four algorithms, including unweighted UniFrac and
weighted UniFrac,26 Spearman rank and binary distance.
Principal component analyses (PCoAs) were used to visualise
data using the functions dudi.pco and s.class of the ade4
package. Correlations were obtained with the function cor.test.
p Values were adjusted using the function p.adjust and the
method of Benjamini and Hochberg.27 Signiﬁcance was
assumed for adjusted p values ≤0.05, if not stated otherwise.
In most instances, for calculations only one sample per indi-
vidual was used (if available for patients with CRC the ON
sample was used, otherwise the mean of all non-cancerous
samples). For the calculation of correlations between the abun-
dance of OTUs and the expression levels of tested genes, both
the ON sample and the mean of all non-cancerous samples were
used because of differences in gene-expression levels between
cancerous and non-cancerous tissues (refer to the ‘Results’
section for details). This was also true when comparing paired
cancerous and non-cancerous tissues.
Because distal and proximal control biopsies were not differ-
ent either in terms of overall microbiota or gene expression (see
below), the average of both samples per individual (if available)
was used for all calculations.
Dietary data
Dietary data were collected using a validated Food Frequency
Questionaire13 (FFQ).
RESULTS
Mucosal microbiota of patients with CRC differs
signiﬁcantly from that of controls throughout the colon
PCoA and comparison of the abundance of single OTU and
genus revealed signiﬁcant differences between the mucosal
microbiota composition of patients with cancer and that of con-
trols (see ﬁgure 1A and online supplementary tables S3–S9).
Patients with cancer had an increased abundance of OTUs classi-
ﬁed as Bacteroides, Roseburia, Ruminococcus, Oscillibacter,
among others and genera previously reported as oral pathogens
(such as Porphyromonas, Peptostreptococcus, Parvimonas,
Fusobacterium among others). Despite the collective differences
between subjects with cancer and controls, the microbiota asso-
ciated with cancerous and non-cancerous tissues within the
same individual did not differ signiﬁcantly (ﬁgure 1B). While
individual bacterial taxa, including Fusobacterium, were more
abundant in some individuals ON the tumour, no single OTU
or genus was found to be signiﬁcantly more or less abundant
(see online supplementary tables S5 and S6). In addition, the
microbiota of individuals with polyps (mostly undiseased tissue
was studied for this group) was found to be signiﬁcantly differ-
ent to that of controls (ﬁgure 1A; range of Pr (>F) 0.0002 to
0.03 for the different distance matrices applied as in online sup-
plementary ﬁgures S1–S4). This suggests that the microbiota
compositional differences in patients with cancer are not
secondary to the cancer per se.
Mucosal microbiota differs between rectal, distal and
proximal CRC
Although most demographic features of the patients with CRC
(see online supplementary table S1) were not associated with a
particular mucosal microbiota proﬁle, the microbiota of distal
and proximal cancers differed signiﬁcantly, both at the level of
the whole community (see ﬁgure 1C and online supplementary
ﬁgures S1–S4) as well as for single OTU and genus (see online
supplementary tables S8 and S9). In particular, the abundances
of Alistipes (p<0.1), Akkermansia (p<0.1), Halomonas and
Shewanella were signiﬁcantly higher in individuals with rectal
and distal cancers. Contrastingly, OTUs classiﬁed as
Faecalibacterium, Blautia and Clostridium were signiﬁcantly
more abundant in individuals with proximal cancer. This differ-
ence in sidedness was also assessed in the control samples. An
equal number of distal and proximal sided control tissue
samples from different individuals was randomly sampled 100
times. For 97% of sample combinations, the microbiota of distal
and proximal control individuals was not signiﬁcantly different.
Thus, it is unlikely that the differences observed between distal
and proximal cancers are due to interindividual differences
rather than the location of the tumour. Administration of differ-
ent bowel preparations for distal (including rectal) and proximal
cancers is also a possible confounding factor. Individuals with
distal and rectal cancers were often administered a full bowel
Gut microbiota
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preparation prior to surgery (see online supplementary table
S1), whereas individuals with proximal cancers were only admi-
nistered two phosphate enemas on the morning of the surgery.
Indeed, signiﬁcant differences in microbiota composition were
found between individuals with different bowel preparations.
However, when excluding proximal cancers, no signiﬁcant dif-
ference in microbiota composition was detected (Pr (>F)=0.12
for unweighted UniFrac distance, no adjustment for multiple
testing) for the different bowel preparations applied. In contrast,
when excluding distal and rectal cancers with full bowel prepar-
ation, the differences in microbiota composition between distal
and rectal versus proximal cancers were still detected (range of
Pr (>F) 0.003–0.02 for the different distance matrices applied).
We conclude that differences in microbiota composition due to
varying bowel preparations cannot be excluded but differences
in microbiota composition between distal and rectal versus
proximal cancers are more robust.
The differences between distal and rectal versus proximal
cancers were also consistent with signiﬁcant differences in
microbiota composition found between individuals with and
without rectal bleeding, the latter being more common in distal
and rectal cancers (see online supplementary ﬁgures S1–S4).
Faecal and mucosal microbiota are signiﬁcantly different
Because of the prognostic importance of early detection of CRC
and the potential testing of faeces for microbial biomarkers, we
assessed whether faecal microbiota proﬁles reﬂected those
found for the mucosa as described above.
The microbiota of paired mucosal and faecal samples from
individuals with CRC (n=32) differed signiﬁcantly (see online
supplementary ﬁgures S1–S4), and this difference was also
found when all available samples (matched and non-matched)
were included in the analysis (ﬁgure 1D). Thus, the relative
abundance of single OTU was only moderately correlated
between paired mucosal and faecal samples (mean of Kendall’s τ
correlation coefﬁcient of 0.20 for all OTUs; see online supple-
mentary table S10a). However, signiﬁcant differences between
the faecal microbiota of controls and patients with CRC were
still detected, both in terms of single organism (Lachnospiraceae
incertae sedis and Coprococcus were signiﬁcantly decreased in
individuals with CRC) as well as overall microbiota (see online
supplementary ﬁgures S1–S4). Thus, even though faecal micro-
biota only partially reﬂects the microbiota at the mucus layer,
differences due to disease status are still evident.
CAGs reveal heterogeneity of CRC-associated microbiota
Although several OTUs (and genera) were more abundant in
CRC, there was considerable heterogeneity, with no single OTU
tested being increased in all individuals with CRC. Therefore,
we analysed the microbiota by determining CAGs, since com-
munity structure can be more informative than abundance dif-
ferences of individual taxa.13 We identiﬁed six robust CAGs or
bacterial clusters in the OTU data set and named them accord-
ing to the most notable characteristic (ﬁgure 2). Among these,
the Firmicutes Cluster 1 and the Bacteroidetes Cluster 1 were
signiﬁcantly less abundant in the microbiota of individuals with
CRC, whereas the Firmicutes Cluster 2, Prevotella Cluster,
Pathogen Cluster and Bacteroidetes Cluster 2 were more abun-
dant in CRC biopsy microbiota (adjusted p value <0.1 for the
latter; ﬁgure 3A). Similar trends were evident for the mucosal
biopsy microbiota of individuals with polyps, albeit not statistic-
ally signiﬁcant in all cases (ﬁgure 3A). The relative abundance of
these CAGs was also signiﬁcantly different by tumour location
—Bacteroidetes Cluster 2 and the Pathogen Cluster were more
abundant in distal cancers, whereas the Prevotella Cluster and
Firmicutes Cluster 2 were only signiﬁcantly more abundant in
individuals with proximal cancers (ﬁgure 3B).
Figure 1 Unweighted UniFrac
principal component analysis; the
microbiota of healthy controls,
individuals with polyps and individuals
with cancer (A) as well as from
individuals with distal, including rectal,
and proximal cancers (C) was
signiﬁcantly different; no difference
was found in microbiota composition
of tumour and paired non-tumour
tissues (B); the faecal microbiota of
both cancer and control individuals
was different from the mucosal
microbiota (D). CRC, colorectal cancer.
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We then examined the potential interactions among the
CAGs, which reﬂect how groups of co-abundant bacteria form
higher level associations into complex microbial ecosystems.13
We observed that the abundances of these CAGs per individual
were negatively or positively correlated with each other par-
ticularly in CRC microbiota (see table 1 for signiﬁcantly corre-
lated CAGs within CRC samples and ﬁgure 4 for
corresponding heat plot). Thus, the separation of the samples
in the PCoA along the X-axis and Y-axis was signiﬁcantly cor-
related with the abundance of the CAGs (ﬁgure 5). Moreover,
a strong correlation was detected between α-diversity and
microbiota structure. The higher microbiota diversity level
strongly correlated with the abundance of the Bacteroidetes
Cluster 2 and Firmicutes Cluster 2 (p=6×10−10 and
p=5×10−25, respectively), whereas a negative correlation was
detected between α-diversity and the abundance of the
Pathogen Cluster (p=3×10−4). Clustering of individuals based
on the (mucosal microbiota) abundance of each of the six bac-
terial clusters revealed four distinct sample groups (ﬁgure 6).
Sample Groups 1 and 2 comprised only individuals with CRC,
which displayed high abundances of the Pathogen Cluster and
the Prevotella Cluster, respectively. Sample Group 3 comprised
mostly healthy controls (70%) and individuals in this group
had high abundances of the Firmicutes Cluster 1. Lastly,
Sample Group 4 contained mostly individuals with CRC (62%)
and elevated abundances of Bacteroidetes Cluster 1 and
Bacteroidetes Cluster 2 (ﬁgures 6 and 7). Firmicutes Cluster 2
was of elevated abundance in CRC samples of Sample Groups
3 and 4.
When comparing the abundance of OTUs in mucosal and
paired faecal samples, the OTUs belonging to the Pathogen
Cluster showed particularly low correlations between paired
faecal and mucosal samples (mean of Kendall’s τ 0.166, see
online supplementary table S10b). Furthermore, the fold-
change in abundance between OTUs of this CAG in mucosal
and faecal microbiota was very high (mean >100, see online
supplementary table S10b). Many of the OTUs with the highest
fold-difference between paired CRC biopsy samples and CRC
faecal samples were classiﬁed as Parvimonas, Anaerococcus,
Streptococcus and Fusobacterium (see online supplementary
table S10b), all bacteria of possibly oral origin. This discrepancy
indicated a strong dilution of the mucosa-associated microbiota
in faeces in individuals with high levels of possibly oral patho-
gens and could mean that these organisms form tight associa-
tions with the mucosa, resembling bacterial bioﬁlms present in
the oral cavity.
Figure 2 Hierarchical Ward-linkage clustering based on the Pearson correlation coefﬁcients of the relative abundance of operational taxonomic
units in mucosal microbiota of 59 individuals with colorectal cancer (CRC) and 56 healthy controls. Co-abundance groups (CAGs) were deﬁned on
the basis of the clusters in the vertical tree and named after their most notable characteristic. Column colour coding is according to legend below.
Row colour coding is according to legend on the left. To the right, the most abundant bacterial genera as well as the most strongly connected
genera in each CAG (ie, genera with the highest numbers of signiﬁcant positive correlations with other members of each respective group) are
listed. HC, healthy control.
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CRC-associated microbiota heterogeneity is validated by
meta-analysis of two previous studies
We investigated if the established CRC-associated microbiota
clusters and microbial heterogeneity could be detected in other
published CRC microbiota data sets.11 21 For better comparabi-
lity, we performed the analysis upon only one sample per
Figure 3 Boxplots of relative abundances of the six co-abundance
groups (CAGs), named bacterial clusters in the following. Four clusters
(Bacteroidetes Cluster 2 (p<0.1), Firmicutes Cluster 2, Pathogen Cluster
and Prevotella Cluster) were of signiﬁcantly increased abundance in
individuals with colorectal cancer (CRC) (59 individuals with CRC, 21
individuals with polyps, 56 healthy controls). Two clusters (Firmicutes
Cluster 1 and Bacteroidetes Cluster 1) were of signiﬁcantly decreased
abundance (A). Bacteroidetes Cluster 2 and Pathogen Cluster,
Firmicutes Cluster 2 and Prevotella Cluster were most often more
abundant in individuals with distal cancers and proximal cancers,
respectively (B). ***p value<0.001; **p value<0.01; *p value <0.05;
p value <0.1.
Figure 4 Hierarchical Ward-linkage clustering based on the Pearson
correlation coefﬁcients of the relative abundance of co-abundance
groups (CAGs) in colorectal cancer (CRC) samples (59 individuals).
p Values for signiﬁcant correlations are shown in table 1. HC, healthy
control.
Table 1 Pearson correlations of CAGs within CRC microbiota data
sets
Cluster 1 Cluster 2 Correlation
Adjusted
p value
Bacteroidetes Cluster 2 Firmicutes Cluster 2 0.235 0.026
Bacteroidetes Cluster 2 Pathogen Cluster −0.209 0.049
Bacteroidetes Cluster 2 Prevotella Cluster −0.310 0.002
Firmicutes Cluster 1 Firmicutes Cluster 2 0.458 2.28E-06
Firmicutes Cluster 1 Pathogen Cluster −0.521 9.11E-08
Firmicutes Cluster 1 Prevotella Cluster −0.187 0.079
Firmicutes Cluster 2 Pathogen Cluster −0.418 1.55E-05
Only correlations with an adjusted p value of <0.1 are shown.
CAGs, co-abundance groups; CRC, colorectal cancer.
Figure 5 Unweighted UniFrac principal component analysis (PCoA)
(mucosa associated microbiota of 59 individuals with colorectal
cancer and 56 healthy controls). The location of samples on the
PCoA is strongly associated with α-diversity and abundance of the
bacterial co-occurrence clusters as deﬁned in ﬁgure 2. Arrows
indicate the direction of correlations for α-diversity (black) and
bacterial co-occurrence networks (colours as in ﬁgure 2) with
location on the PCoA. The distance from the origin and the direction
correspond to the vector of x- and y-axis Spearman-correlation
coefﬁcient.
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individual (ie, the tumour sample), for both the publicly avail-
able data and our data. Additionally, we removed healthy
control samples from our data set, as such samples were not
available for the other two studies. Strikingly, very similar
microbial co-occurrence networks were identiﬁed in all three
data sets (see online supplementary ﬁgures S5–S8).
Furthermore, the strong association of the Firmicutes Cluster 2
with elevated α-diversity that we described above, and the
Figure 6 Hierarchical Ward-linkage clustering of biopsy samples based on the Pearson correlation of the abundance of bacterial co-occurrence
clusters in each sample (59 individuals with colorectal cancer (CRC) and 56 healthy controls). Four distinct groups of samples were deﬁned. Sample
Group 1 and Sample Group 2 only comprises individuals with cancer and display high abundances of the Pathogen Cluster and the Prevotella
Cluster, respectively. Sample Group 3 contains mostly samples from healthy controls, which have a high relative abundance of Firmicutes Cluster
1. Sample Group 4 comprises 60% individuals with cancer with high relative abundances of Bacteroidetes Clusters 1 and 2. Firmicutes Cluster 2 was
found to be most abundant in individuals with CRC from Sample Groups 3 and 4. Column annotation: cancer biopsy (blue) and control biopsy (red).
Figure 7 Schematic representation of relative abundance distribution for each bacterial co-occurrence cluster (colours bars as deﬁned in ﬁgure 2)
in each Sample Group (ﬁgure 6). Clear differences in relative abundance for each bacterial cluster in each Sample Group are evident. Additionally,
individuals in Sample Group 1 were associated with low α-diversity, whereas individuals in Sample Groups 3 and 4 were associated with high
α-diversity. Signiﬁcant difference for each Sample Group compared with each other Sample Group in terms of α-diversity is indicated above bar.
Brackets indicate p<0.1.
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association of the Pathogen Cluster with decreased α-diversity,
were both consistently detected (see online supplementary
ﬁgure S9). Additionally, the four sample groups identiﬁed in our
cohort, containing individuals with high mucosal abundance of
the different microbial co-occurrence networks (ﬁgure 6), were
validated in large part in the other two data sets (see online sup-
plementary ﬁgures S10–S13). Lastly, we analysed the data at the
level of the bacterial genus, which allowed additional compari-
son of microbial abundances between healthy controls of the
present cohort with microbial abundances in tumour samples of
the two publicly available datasets. Mostly, similar bacterial
genera were found to be less and more abundant in individuals
with CRC throughout all three studied cohorts (see online sup-
plementary ﬁgure S14).
Distinctive mucosal gene expression proﬁles are associated
with bacterial CAGs
We quantiﬁed the expression of 18 human genes known to be
involved in inﬂammation and progression of CRC (see online
supplementary table S2a). Thirteen genes were differentially
expressed in patients and controls (see online supplementary
table S2b), and the expression was signiﬁcantly correlated with
the abundance of several OTUs (see ﬁgure 8 and online supple-
mentary table S11). More importantly, the mucosal abundance
of the six bacterial clusters was associated with distinct mucosal
gene expression proﬁles (table 2). The two clusters that were of
decreased abundance in individuals with CRC (Firmicutes
Cluster 1 and Bacteroidetes Cluster 1) were negatively corre-
lated with the expression of genes such as CXCL1, SERPINE1,
and interleukins (ILs) 17a and 23. Contrastingly, the abundance
of the cancer-associated clusters Prevotella Cluster and Pathogen
Cluster was positively correlated with the expression of these
genes. For the Bacteroidetes Cluster 2 and Firmicutes Cluster 2
on the one hand and the Pathogen Cluster on the other hand,
all of which show signiﬁcantly increased abundance in indivi-
duals with CRC, opposing correlations were detected (table 2
and ﬁgure 9; individuals with CRC only). For example, the
abundance of the former clusters was signiﬁcantly negatively
correlated with the expression of CCL20 and IL-17a, whereas
the abundance of the Pathogen Cluster was positively correlated
with the expression of such genes (table 2 and ﬁgure 9). At the
level of single OTU, similar patterns were observed (ﬁgure 8).
Importantly, the associations between the abundance of bacterial
clusters and gene-expression levels were also detected in healthy
tissue from patients with CRC (see online supplementary
table S12), indicating that the microbiota-associated changes of
mucosal gene-expression proﬁles could be involved in the early
stages of disease development. In summary, the different
mucosal microbiota structures detected were associated with dif-
ferent mucosal gene expression proﬁles.
DISCUSSION
This study conﬁrms that the microbiota of patients with CRC
differs from that of controls, but alterations were not restricted
to neoplastic tissue and differed between subjects with proximal
and distal, including rectal, tumours. Heterogeneity of the
microbiota was particularly evident when it was studied at the
level of CAGs rather than at the level of individual organisms or
taxa and when correlated with the patterns of expression of
host immune-inﬂammatory response genes.
Previously, only a minority of the studies investigating the
mucosal microbiota associated with CRC included healthy indi-
viduals as controls.28 29 Usually, paired undiseased tissue from
individuals with CRC was used for comparison.7 8 Furthermore,
paired faecal and mucosal samples have rarely been studied.11
To achieve a comprehensive analysis, we included mucosal and
faecal microbiota in addition to gene expression proﬁles of
healthy individuals and patients with CRC.
It was striking that the mucosal microbiota of paired samples
(‘ON’ vs ‘OFF’ tumour) was very similar with regard to both
individual taxa and the overall composition of the microbiota.
In contrast, the microbiota was signiﬁcantly different between
controls and cases, and between mucosal biopsies from subjects
with polyps (even though we mostly sampled undiseased tissue
from such individuals) and controls. It seems likely that a
CRC-distinctive microbiota is already present and possibly
involved in the early stages of cancer development and less
likely that a localised tumour changes the entire colonic micro-
environment, to which the microbiota then adapts.
Taxa that were signiﬁcantly more abundant in patients with
CRC were prominent in only a subset of patients with CRC.
For example, OTUs most closely related to Fusobacterium,
Peptostreptococcus or Parvimonas were markedly elevated in
only 20–30% of individuals with CRC. However, it was pos-
sible to deﬁne four microbial clusters (higher level structures) of
the CRC-associated microbiota of which at least one was ele-
vated more than twofold (compared with the mean in all
control samples) in all but one of the individuals with CRC.
Importantly, we were able to verify our ﬁndings with regard to
microbial heterogeneity associated with CRC patients by com-
parison with two previous studies.11 21 However, differences
were also observed. For example, we deﬁned one CAG in the
continental European cohort,21 which comprised genera such as
Variovorax, Caulobacter and Comamonas. These bacterial taxa
were not prevalent in our cohort which is possibly due to differ-
ent 16S rRNA regions studied, as well as possibly differences in
DNA extraction methodology. Additionally, tumour microbiota
data sets from the American/European/Vietnamese cohort21 dis-
played very high abundances of Fusobacterium spp. in compari-
son to both the Irish and the continental European cohort.
Geographical differences (environmental reservoirs for intestinal
bacteria) could be an additional factor in this case.
Arumugam et al have previously proposed a stratiﬁcation of
individuals into three distinct bacteriotypes or enterotypes.30 We
detected striking similarities with this concept when grouping
individuals into four subgroups based on their abundance of the
six bacterial clusters (ﬁgures 6 and 7), but our data support a
concept of stratiﬁcation based on bacterial abundance gradients
rather than discrete bacteriotypes. Importantly, particularly when
only considering the microbiota associated with tumours (see
online supplementary ﬁgure S7) from the Irish cohort, the two
bacterial clusters associated with healthy individuals were still
detected (Firmicutes Cluster 1 and Bacteroidetes Cluster 1) and
were correlated with the presence of two CRC-associated bacter-
ial clusters (Firmicutes Cluster 2 and Bacteroidetes Cluster 2,
respectively). The third and fourth clusters represent the
Prevotella Cluster and the Pathogen Cluster, which were both
clearly associated with the presence of CRC (ﬁgures 6 and 7).
This indicates that CRC-associated microbiota arises from a
context of three different baseline microbiotas (Firmicutes
Cluster 1, Bacteroidetes Cluster 1 and Prevotella Cluster). From
a functional point of view, the microbiota of individuals with
high abundances of the Prevotella Cluster and the Pathogen
Cluster might inﬂuence the development of CRC through modu-
lating the expression of immunoinﬂammatory response genes.
Contrastingly, CRC-associated microbiota of the Bacteroidetes
Cluster 2 and Firmicutes Cluster 2 type were negatively corre-
lated with the expression of such genes, and are therefore likely
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to exhibit other properties, which might inﬂuence the develop-
ment of CRC.
In addition, the expression of several genes implicated in the
progression or severity of cancer and inﬂammation, such as
CXCL1, SERPINE-1, STAT3 and ILs, was signiﬁcantly corre-
lated with the abundance proﬁles of some OTUs and/or CAGs.
Surprisingly, the abundance of the Firmicutes Cluster 2 and
Bacteroidetes Cluster 2, which were increased in abundance in
individuals with CRC, was correlated with a mucosal
gene-expression proﬁle more resembling that of a healthy
mucosa, whereas the Pathogen Cluster and Prevotella Cluster
were correlated with high expression levels of CCL20, CXCL1,
IL-17a, IL-23, IL-8, MMP13 and SERP1 (ﬁgures 8 and 9).
CXCL1 expression has been shown to increase the survival of
cancerous cells31 and to promote angiogenesis in CRC.32
Previous reports linked an increased TH17/TH1 ratio in the
tumour microenvironment with a poor prognosis for CRC.9
Increased tumorigenesis has been described in mice colonised
with enterotoxigenic B. fragilis in an IL-23-dependent and
STAT3-dependent manner associated with TH17 activation.5
Moreover, IL-23-producing myeloid cells, likely activated
through TLR-dependent detection of microbial products, elicit a
tumorous IL-17 response and tumour progression, possibly
through STAT3 signalling.33 The association of the Pathogen
Cluster in this study with IL-17a, IL-23 and CCL20 (which
binds to the receptor CCR6, which is extracellularly expressed
by TH17 cells) is a strong indicator that this CAG is associated
with an increased TH17 response and may be associated with a
poor prognosis for CRC. In contrast, the negative association of
the Bacteroidetes Cluster 2 and Firmicutes Cluster 2 with the
Figure 8 Network plots of operational taxonomic units (OTUs) based on the mucosal abundance of each OTU in 59 individuals with colorectal
cancer and 56 healthy controls. (A) Each node (circle) represents a bacterial OTU. The size of each node correlates to the mean abundance of each
OTU across all samples. (B–D) Nodes (OTUs) are shown if the abundance of the respective OTU was signiﬁcantly correlated with the expression of
IL-17a (B), IL-8 (C) or IL-23 (D). Upward facing triangle: positive correlation; downward facing triangle: negative correlation. (A–D) The width of each
edge corresponds to the p value of the correlation between each respective node (lower p value, higher line-width). The location of each node was
determined by a principal component analysis of the correlation distance as described in ‘Material and methods’ section. Colour of each node
according to the co-abundance groups as in ﬁgure 2.
Gut microbiota
641Flemer B, et al. Gut 2017;66:633–643. doi:10.1136/gutjnl-2015-309595
group.bmj.com on January 22, 2018 - Published by http://gut.bmj.com/Downloaded from 
expression of IL-17a and CCL20 suggest that these CAGs are
associated with a decreased TH17 response and, perhaps, a
better prognosis for CRC.
It is noteworthy that the Pathogen Cluster comprises several
OTUs most closely related to genera found in the oral cavity,
such as Fusobacterium, Porphyromonas, Anaerococcus,
Parvimonas, Granulicatella and Prevotella. In this respect, our
data support the recently presented ‘oral microbiome’ hypoth-
esis34 at least for a subset of CRCs. Furthermore, OTUs from
the Pathogen Cluster were only detectable in low abundance in
the faecal microbiota (see online supplementary table S10b),
indicating a tight association with the cancerous tissue. It is con-
ceivable that polymicrobial colonisation of the tumour by bac-
teria closely related to oral pathogens, possibly similar to a
microbial bioﬁlm, could promote tumorigenesis by altering the
tumour microenvironment and eliciting an increased TH17
response, which is associated with a poor prognosis in CRC.
The differences in the microbiota of patients with proximal
and distal cancers found here are an additional level of tumour–
host heterogeneity. We identiﬁed a CAG (Firmicutes Cluster 2),
which was more often found to be increased in proximal
cancers and associated with a gene expression proﬁle more
similar to the control cohort (and possibly a decreased TH17
response). In particular, the abundance of the Bacteroidetes
Cluster 2 and Firmicutes Cluster 2 was negatively correlated
with the expression of IL-17a and CCL20, a chemokine shown
to promote cancer cell proliferation and migration35 and which
binds to the TH17-cell receptor CCRC6. Several microbial and
host factors contribute to differences in the topographical distri-
bution of cancers over the long axis of the gut.36 The biological
signiﬁcance of difference in the microbiota in the proximal and
distal colon is not currently clear but it is noteworthy that right
and left colon are embryologically distinct, and have different
blood supply and innervation. Furthermore, cancers of the right
colon present and behave differently clinically to those of the
distal colon. The relationship between these facts and the dis-
tinctiveness of the microbiome in the right and left colon is
uncertain but worthy of future exploration.
There are aspects of this study that can be improved in
future. First, although we could not ﬁnd differences between
the composition of the microbiota of individuals with or
without neoadjuvant therapy, presurgical treatment is potentially
a confounding variable that is currently being tested more sys-
tematically by us. Second, bowel preparation has been shown to
effect microbiota composition.37 Whereas we cannot exclude an
impact of the varying types and amounts of bowel preparation
administered on the microbiota, the detected differences in the
microbiota structure of healthy controls and individuals with
CRC as well as distal, including rectal, and proximal CRCs were
stronger than differences related to bowel preparation. Third,
we found evidence that individuals with CRC have different
dietary habits than healthy controls (see online supplementary
ﬁgure S15). However, no signiﬁcant association was found
between habitual diet and structure of the microbiota, perhaps
because of insufﬁcient dietary difference within the cohort.
Furthermore, although dietary assessments by FFQ have been
highly informative in assessing the impact of diet on the com-
position of the microbiota in elderly subjects,13 a diet–micro-
biota link probably relates to dietary intake many years before
the age of presentation with CRC. Consequently, contemporan-
eous dietary assessments are less likely to be informative.
In conclusion, distinct higher level structures in the microbiota
can be employed to stratify individuals for their risk of presenting
with CRC. Furthermore, CRC-associated microbiota is
Table 2 Correlations between the expression of genes involved in
inflammation and cancer progression and the abundance of CAGs
Bacterial cluster Gene
Spearman correlation
coefficient
Adjusted
p value
Bacteroidetes Cluster 1 IL-23 −0.26874 0.097132
Bacteroidetes Cluster 1 MMP13 −0.29524 0.099793
Bacteroidetes Cluster 1 MyC −0.32069 0.078796
Bacteroidetes Cluster 1 SERP1 −0.47544 0.003827
Bacteroidetes Cluster 1 STAT3 −0.31402 0.094772
Bacteroidetes Cluster 2 CCL20 −0.31188 0.092787
Bacteroidetes Cluster 2 CXCL1 −0.38364 0.04265
Bacteroidetes Cluster 2 IL-17a −0.46708 0.009261
Bacteroidetes Cluster 2 IL-23 −0.3362 0.058422
Bacteroidetes Cluster 2 MMP13 −0.31122 0.099793
Bacteroidetes Cluster 2 MyC −0.37734 0.049169
Bacteroidetes Cluster 2 STAT3 −0.46631 0.005726
Firmicutes Cluster 1 IL-17a −0.48057 0.009261
Firmicutes Cluster 1 IL-23 −0.30634 0.069269
Firmicutes Cluster 1 MMP13 −0.32098 0.099793
Firmicutes Cluster 2 IL-17a −0.39022 0.028904
Pathogen Cluster CCL20 0.327009 0.092787
Pathogen Cluster IL-17a 0.461291 0.009261
Pathogen Cluster IL-23 0.359091 0.058422
Pathogen Cluster MMP13 0.292739 0.099793
Prevotella Cluster MMP13 0.294723 0.099793
Correlations are shown only for those with an adjusted p value of <0.1.
CAGs, co-abundance groups;
Figure 9 Unweighted UniFrac principal component analysis (PCoA) of
mucosal microbiota associated with samples from individuals with
colorectal cancer (30 ON samples, 18 OFF samples). Arrows indicate
the direction of correlations for the expression of several genes possibly
indicative of a TH17 response (CCL20, IL-17a) as well as other
interleukins, CXCL1, MMP13 and SERP1 (dashed arrows, p value <0.1),
α-diversity (black) and bacterial co-occurrence networks (colours as in
ﬁgure 2) with location on the PCoA plot. The distance from the origin
and the direction corresponds to the vector of x- and y-axis correlation.
Colour of circles represents abundance of the Pathogen Cluster in each
sample (red: high, blue: low).
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differentially correlated with distinct patterns of gene expression
for host immunoinﬂammatory responses. Longitudinal studies
are required to further assess the predictive value of the ﬁndings
as biomarkers of disease risk. In addition, the potential to modify
the microbiota in at-risk subjects merits exploration.
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